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ABSTRACT
Previous studies have demonstrated that glucocorticoid hormones, including 
dexamethasone, induced alterations in intracellular calcium homeostasis in acute 
lymphoblastic leukemia (ALL) cells. However, the mechanism by which intracellular 
calcium homeostasis participates in dexamethasone sensitivity and resistance on ALL 
cells remains elusive. Here, we found that treatment of cells with dexamethasone 
resulted in increased intracellular calcium concentrations through store-operated 
calcium entry stimulation, which was curtailed by store-operated calcium channel 
blockers. We show that BAPTA-AM, an intracellular Ca2+ chelator, synergistically 
enhances dexamethasone lethality in two human ALL cell lines and in three primary 
specimens. This effect correlated with the inhibition of the prosurvival kinase ERK1/2 
signaling pathway. Chelating intracellular calcium with Bapta-AM or inhibiting ERK1/2 
with PD98059 significantly potentiated dexamethasone-induced mitochondrial 
membrane potential collapse, reactive oxygen species production, cytochrome c 
release, caspase-3 activity, and cell death. Moreover, we show that thapsigargin 
elevates intracellular free calcium ion level, and activates ERK1/2 signaling, resulting 
in the inhibition of dexamethasone-induced ALL cells apoptosis. Together, these 
results indicate that calcium-related ERK1/2 signaling pathway contributes to protect 
cells from dexamethasone sensitivity by limiting mitochondrial apoptotic pathway. 
This report provides a novel resistance pathway underlying the regulatory effect of 
dexamethasone on ALL cells.
INTRODUCTION
Glucocorticoids are the most common compounds 
used in the treatment of lymphoid malignancies, including 
acute lymphoblastic leukemia (ALL), because of their 
abilities to induce cell death [1]. However, up to ~20% 
patients with leukemia relapse and become resistant to 
glucocorticoids [2]. Glucocorticoid-induced apoptosis is 
generally via a genomic mechanism and mediated by the 
activation of glucocorticoid receptor (GR), which is, in the 
cytosol, sequestered and bound to heat shock proteins in 
its inactive state [3]. GR is expressed throughout all cells 
of the body [4], including B cells [2]. When glucocorticoid 
binds to the GR, the complex is translocated to the nucleus 
to activate or inhibit target genes transcription [5].
Calcium ions are key regulators of several cellular 
mechanisms, including cell growth and death [6]. It has 
been reported that glucocorticoids (dexamethasone or 
corticosterone) induced a decrease in [Ca2+]i in neurons 
and astrocytes [7], and in T lymphocytes [8]. These 
observations were opposite to many reports indicating 
that glucocorticoid increases Ca2+ signaling in murine [9] 
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and human [10] lymphoma cell lines. Thereby, how the 
Ca2+ signaling participates in glucocorticoids-induced 
cell death is not entirely clear. Previous studies from our 
group demonstrated that TRPC3 Ca2+ channel inhibitor 
(Pyr3) enhances dexamethasone sensitivity and apoptosis 
through the distraction of dexamethasone-mediated Ca2+ 
signaling in ALL cells and primary blasts [11]. Because 
we demonstrated that depletion of intracellular calcium 
increased by dexamethasone, enhanced dexamethasone-
mediated apoptosis of ALL cells [11], we here studied the 
mechanism by which intracellular calcium signal participates 
in dexamethasone sensitivity and resistance in ALL cells.
The mitogen-activated protein kinase (MAPK) 
signaling pathway regulates many cellular processes 
including proliferation, differentiation, inflammation, cell 
stress response, cell division, metabolism, motility and 
apoptosis [12]. Increasing evidence reveals the implication 
of mitogen-activated protein kinases (MAPKs) pathway in 
the regulation of glucocorticoids sensitivity in ALL cells [1, 
2], but the mechanism by which MAPKs activate or inhibit 
glucocorticoids sensitivity and resistance remains unknown. 
In several cell types, as well as cancer cells, ERK1/2 
signaling pathway is a significant downstream substrate 
for Ca2+ ions, thus, increases in [Ca2+]i phosphorylated 
ERK1/2 proteins [13, 14]. Therefore, in the present 
work, we investigated whether dexamethasone induces 
apoptosis is attenuated by Ca2+-dependent activation of 
MAPK/ERK pathway. We report here, that calcium-related 
ERK1/2 signaling pathway contributes to protect leukemic 
cells from dexamethasone sensitivity, describing a new 
mechanism of resistance pathway underlying the regulatory 
effect of dexamethasone on ALL cells.
RESULTS
Bapta-AM increases sensitivity to 
dexamethasone in ALL cell lines
Our recent studies have shown that TRPC3 Ca2+ 
channel inhibitor (Pyr3) enhances dexamethasone 
sensitivity in ALL cells by reducing Ca2+ signaling 
[11]. To investigate the role of cytosolic Ca2+ in 
dexamethasone-induced leukemic cells apoptosis, first of 
all, we treated ALL cells with or without dexamethasone 
for 48 h following pre-incubation with or without 1,2-
bis (2-aminophenoxy) ethane-N,N,N,N-tetraacetic acid 
(Bapta-AM), an intracellular Ca2+ chelator. We found that 
ALL cell lines viability was not significantly modified by 
a 48-hours treatment with Bapta-AM (5 μM) alone, while 
treatment with dexamethasone (100 nM) alone decreased 
cell viability in both Nalm-6 (Figure 1A) and Reh (Figure 
1B) cell lines. However, association of dexamethasone 
with Bapta-AM markedly decreased cell viability when 
compared to dexamethasone alone (Figure 1A, 1B). The 
effect of dexamethasone or Bapta-AM alone on cell death 
was dose-dependent and co-treatment potentiated this 
effect. Concentration of dexamethasone as low as 50 
nM significantly decreased cell viability in association 
with 5 μM of Bapta-AM (Figure 1C). The dose-response 
graph of Bapta-AM indicated that concentrations as low 
as 5 μM Bapta-AM significantly increased the lethality 
of 100 nM dexamethasone in ALL cell lines (Figure 1D). 
Furthermore, dexamethasone in association with Bapta-
AM induced significant amount of sub-G1 apoptotic 
cell population compared with dexamethasone alone 
treatment (Figure 1E, 1F). To confirm the role of Bapta-
AM in dexamethasone-induced ALL cell lines apoptosis, 
we analyzed the apoptotic status in these cells using 
Annexin V-FITC/PI staining. The apoptosis rate was 
slightly increased with Bapta-AM or dexamethasone alone 
treatment, but significantly increased by co-treatment 
in both ALL cell lines when compared to control or 
dexamethasone alone (Figure 1G, 1H), confirming the 
results obtained by the MTT assay. We next examined 
whether the effect on cell death induced by Bapta-
AM with dexamethasone is synergistic or additive. 
Isobologram analysis [15] was used to analyze effects 
of drug combinations. Combination index (CI) value <1, 
=1 or >1 indicates that the drugs are synergistic, additive 
or antagonistic, respectively. The combination of 5 μM 
Bapta-AM with 100 nM of dexamethasone produced 
a significant synergistic effect in Nalm-6 and Reh cells 
with a combination index ranging from 0.58 to 0.45, 
respectively (Figure 1G).
Bapta-AM increases dexamethasone-induced 
apoptosis via regulating mitochondrial functions 
in ALL cell lines
Because of the fundamental role of mitochondria 
in cell apoptosis, we next determined whether the effect 
of Bapta-AM on dexamethasone-induced ALL cells 
apoptosis was mediated through modulating mitochondrial 
functions. To this end, ALL cells were pretreated with or 
without Bapta-AM (5 μM) for 30 min and then exposed 
to dexamethasone (100 nM) for 24 h. The dissipation of 
mitochondrial membrane potential (Δψm), an early event 
for cell apoptosis, was detected by JC-10, a lipophilic 
cationic dye. As shown in Figure 2A, a green fluorescence 
represents depolarized mitochondria in ALL cells. In 
agreement with the apoptosis results, dexamethasone-
induced Δψm collapse (Figure 2A, 2B) was significantly 
enhanced by the intracellular Ca2+ chelator Bapta-AM. As 
the loss of mitochondrial membrane potential is known 
to trigger reactive oxygen species (ROS) production 
[16], the possible implication of ROS in ALL cells 
apoptosis induced by dexamethasone in the presence of 
Bapta-AM was investigated. By using cell permeable 
dihydrorhodamine 123 (DHR123), a green fluorescence 
probe, we found that Bapta-AM enhanced the ability of 
dexamethasone to induce ROS production (Figure 2C, 2D). 
A consequence of ROS production and Δψm collapse is the 
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initiation of mitochondria-mediated cell apoptosis cascade 
in which cytochrome c release and caspase-3 activity 
play a critical role [17]. We next determined whether 
the influence of Bapta-AM on dexamethasone-induced 
apoptosis is associated with the release of cytochrome c 
and the activity of caspase-3. As shown in Figure 2, both 
cytochrome c release (Figure 2E) and caspase-3 activity 
(Figure 2F) induced by dexamethasone were markedly 
potentiated by Bapta-AM. These data, together with the 
results obtained above, suggest that the intracellular Ca2+ 
contributes to attenuate dexamethasone-induced apoptosis 
in ALL cells by limiting Δψm collapse, ROS production, 
and cytochrome c release from mitochondria followed by 
caspase-3 activity. Furthermore, the potentiating effect 
of dexamethasone-mediated apoptosis with Bapta-AM 
may not depend on mitochondrial calcium release in ALL 
cells, indeed, as shown in Figure 2G, measurement of 
mitochondrial Ca2+ indicated that the intracellular Ca2+ 
chelator notably abolished dexamethasone-mediated 
mitochondrial Ca2+ release.
Dexamethasone induces cytosolic calcium 
release and SOCE and co-treatment with 
dexamethasone and SOC inhibitors markedly 
enhances ALL cells death
We next sought to examine the effect of 
dexamethasone on Ca2+ signaling in ALL cell lines. As 
shown in Figure 3A and 3B, addition of dexamethasone 
evoked an increase in intracellular free Ca2+ concentrations 
([Ca2+]i) in both ALL cell lines, and dexamethasone-
induced increases in [Ca2+]i were significantly higher 
in Ca2+-containing as compared with Ca2+-free buffer 
(Figure 3A, 3B), suggesting that dexamethasone 
significantly raised the peak of the Ca2+ elevation 
resulting from extracellular Ca2+ influx. To elucidate 
whether dexamethasone-mediated intracellular calcium 
elevation is contributed, as per capacitative model, by 
the opening of store-operated Ca2+ (SOC) channels, we 
conducted experiments in calcium buffer in the presence 
of SKF96365 and 2-aminoethoxydiphenyl borate (2-
Figure 1: Bapta-AM markedly enhances dexamethasone-induced cell death, cell cycle disruption and apoptosis in 
ALL cell lines. Nalm-6 (A) and Reh (B) cells were treated with Bapta-AM (5 μM) and dexamethasone (Dex, 100 nM) alone or in 
combination for 48 h. Cell death was detected by MTT metabolic colorimetric assay. Data are representative of triplicate experiments. (C) 
ALL Reh cells were treated for 48 h with increasing concentrations of dexamethasone (Dex) alone or in association with Bapta-AM (5 μM). 
(D) ALL Reh cells were treated for 48 h with indicated concentration of Bapta-AM alone or in association with dexamethasone (Dex, 100 
nM). The values of control cells were considered as 100%. Data represent the means ±S.E.M. (n=3). *P<0.05 vs Dex or Bapta-AM alone 
treatment. Cell cycle distribution (E, F) and apoptosis (G, H) were determined respectively by PI staining and Annexin V/FITC-PI staining 
followed by FACS analysis. *P<0.05 vs dexamethasone alone treatment (E, F). (H) The percentage of apoptotic cells was calculated by the 
percentage of annexin V-FITC positive and annexin V-FITC/PI-positive population. Combination index (CI) value < 1 (0.58 in Nalm-6 and 
0.45 in Reh cells) indicates that the drugs are significantly synergistic. Data represent the mean ± S.E.M. (n=3).
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ABP), the SOC channel blockers [18, 19]. We observed 
that blockers of SOC channels significantly decreased 
dexamethasone-induced increases in [Ca2+]i in both ALL 
cell lines (Figure 3C, 3D). In addition, preincubation 
with U73122, an inhibitor of phospholipase C (PLC) 
significantly curtailed dexamethasone-induced increases in 
[Ca2+]i in these cells (Figure 3C, 3D). To further examine 
whether store operated Ca2+ entry (SOCE) is activated 
following dexamethasone stimulation in ALL cells, SOCE 
was assessed according to the commonly used protocol 
[20]. Thus, endoplasmic reticulum (ER) Ca2+ store is first 
completely depleted in Ca2+ free medium by application 
of 1 μM thapsigargin (TG, a noncompetitive inhibitor of 
the sarco/ER Ca2+-ATPase) and SOCE is then evaluated 
by addition of 1.8 mM CaCl2 in the extracellular medium. 
As illustrated in Figure 3E, dexamethasone significantly 
potentiated the peak of TG-induced SOCE. Moreover, 
when ALL cells were exposed to 2-APB (SOC blocker), 
the dexamethasone-induced increase in SOCE was 
significantly blunted (Figure 3E). Taken together, these 
results suggest that the dexamethasone-stimulated increase 
in calcium entry is at least in part SOCE dependent. To 
validate the possibility that suppression of dexamethasone-
activated SOCE can enhance the dexamethasone-mediated 
cell death, we employed two pharmacological inhibitors, 
SKF 96365 and 2-APB, of the Ca2+ SOC channels [18, 
19]. We observed that ALL cell lines viability was not 
significantly modified by a 48 h treatment with 2-APB 
(5 μM) and SKF 96365 (5 μM) alone, while co-treatment 
with dexamethasone (100 nM) significantly decreased 
cell viability in both Reh (Figure 3F) and Nalm-6 (Figure 
3G) cell lines at 48 hrs, compared to dexamethasone alone 
treatment.
Bapta-AM potentiates the dexamethasone-
induced inhibition of ERK1/2 signaling in ALL 
cells by chelating Ca2+ signaling
Since dexamethasone elicited strong [Ca2+]
i signaling, we then examined the effect of Bapta-AM 
on dexamethasone-induced cytosolic Ca2+ elevation. To 
this end, ALL cells were pre-incubated with or without 
Bapta-AM (5 μM), an intracellular Ca2+ chelator, and then 
exposed or not to dexamethasone (100 nM). We observed 
that in the presence of Bapta-AM, dexamethasone failed 
to trigger cytosolic calcium elevation in both ALL cell 
lines (Figure 4A, 4B). In several cell types, as well as 
cancer cells, ERK1/2 signaling pathway is a significant 
Figure 2: Co-treatment with dexamethasone and Bapta-AM markedly increases mitochondrial membrane potential 
depolarization, reactive oxygen species production, cytochrome c release and caspase 3 activity in ALL cells. Cells 
were treated with Bapta-AM (5 μM) and dexamethasone (Dex, 100 nM) alone or in combination for 24 h. Images acquired with Zeiss 
Axiovert 200M fluorescence microscope after JC-10 (A) and DHR 123 (C) staining using FITC channel. The fluorescence intensity for 
both mitochondrial membrane potential changes (B) and intracellular reactive oxygen species generation (D) was measured with SAFAS 
Xenius XC Spectrofluorometer. The bar graphs of mean fluorescence intensity representing cytochrome c release (E) caspase-3 activity (F) 
and mitochondrial calcium (G). Data represent the mean ± S.E.M. (n=3). *P<0.05 vs dexamethasone alone treatment; #P<0.05 vs control.
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downstream substrate for Ca2+ ions, thus, increases in 
[Ca2+]i phosphorylated ERK1/2 proteins [13]. We then 
examined whether Bapta-AM's Ca2+ chelation influenced 
the effect of dexamethasone on ERK1/2 phosphorylation. 
Interestingly, it was found that dexamethasone slightly 
decreased the phosphorylation of ERK1/2, whereas 
Bapta-AM completely suppressed ERK1/2 activation 
(Figure 6C, 6D), suggesting that Ca2+ is indeed a critical 
upstream factor that determined ERK1/2 phosphorylation. 
Concurrently, in comparison to dexamethasone alone 
treatment, Bapta-AM greatly enhanced dexamethasone-
induced inhibition of ERK1/2 phosphorylation, which 
may be due to the inhibitory action of this Ca2+ chelator 
on dexamethasone-induced Ca2+ influx (Figure 4C, 4D). 
These results indicated that intracellular calcium attenuates 
dexamethasone-induced inhibition of ERK1/2. Suggesting 
that dexamethasone elevated cytosolic Ca2+ could trigger 
the activation of ERK1/2 signaling pathway.
Pharmacological inhibition of ERK1/2 
potentiates dexamethasone sensitivity and 
apoptosis in ALL cells
In order to shed light on the involvement of ERK1/2 
pathway in dexamethasone sensitivity and apoptosis, we 
used PD98059, a selective inhibitor of MEK. PD98059 has 
been shown to inhibit activation of MEK targets including 
ERK1/2 [1]. As shown in Figure 5A, pretreatment of ALL 
cells with PD98059 inhibited phosphorylation of ERK1/2 
regardless of dexamethasone treatment. ALL cell lines 
viability was slightly modified by a 48-hours treatment 
with PD98059 (5 μM) alone, while treatment with 
Figure 3: Dexamethasone stimulates intracellular Ca2+ release and SOCE and co-treatment with dexamethasone and 
SOC inhibitors markedly enhances ALL cells death. Cells were loaded with Fura-2/AM, and the changes in intracellular Ca2+, 
[Ca2+]i, (F340/F380) were monitored. (A, B) The colored time-lapse images and the graphical representation show the changes in [Ca2+]i 
evoked by dexamethasone (Dex), in Reh and Nalm-6 cell lines, respectively, in Ca2+-containing and in Ca2+-free buffer. (C, D) ALL cells 
before exposure to 100 nM dexamethasone (Dex) in Ca2+ buffer were preincubated (20 minutes) with U73122 (10 μM), SKF96365 (10 
μM) or 2-APB (10 μM). Data are mean ± SEM (n = 5). (E) Effect of dexamethasone (Dex) on SOCE activation in ALL cells. ALL cells ER 
calcium stores were depleted with thapsigargin (TG, 1 μM) in calcium-free suspension medium in the presence or absence of 2-APB (10 
μM), cells were then treated without or with 100 nM dexamethasone, followed by addition of 1.8 mM CaCl2. Data are mean ± SEM (n = 3). 
Reh (F) and Nalm-6 (G) cells were treated with SOC inhibitors (SKF 96365, 5 μM and 2-APB, 5 μM) and dexamethasone (100 nM) alone 
or in combination for 48 h. Cell death was detected by MTT metabolic colorimetric assay. Data are representative of triplicate experiments. 
*p <0.001 vs. control; #p <0.001 vs. Dex.
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Figure 4: Bapta-AM potentiates dexamethasone-induced inhibition of ERK1/2 signaling by chelating Ca2+ signaling 
in ALL cells. (A, B) Cells were exposed to 100 nM dexamethasone (Dex) with or without preincubated (20 minutes) with Bapta-AM (5 
μM) in Ca2+ buffer and the changes in [Ca2+]i were monitored as Figure 5. (C) ALL cells were preincubated (20 min) with Bapta-AM (5 
μM) in Ca2+ buffer and then exposed to 100 nM Dex for 5 min. Cell lysates were subjected to western blotting analysis with the indicated 
antibodies, along with quantification (D). Data represent the mean ± SEM (n=3).
Figure 5: Pharmacological inhibition of ERK1/2 potentiates dexamethasone sensitivity in ALL cells. ALL cells were 
preincubated (20 min) with PD98059 (5 μM) and then exposed to 100 nM dexamethasone (Dex) for 5 min. Cell lysates were subjected 
to western blotting analysis with the indicated antibodies, along with quantification (A). Nalm-6 (B) and Reh (C) cells were treated with 
PD98059 (5 μM) and dexamethasone (100 nM) alone or in combination for 48 h. Cell death was detected by MTT metabolic colorimetric 
assay. Data are representative of triplicate experiments. (D) ALL Reh cells were treated for 48 h with increasing concentrations of 
dexamethasone (Dex) alone or in association with PD 98059 (5 μM). (E) ALL Reh cells were treated for 48 h with indicated concentration 
of PD98059 alone or in association with Dex (100 nM). The values of control cells were considered as 100%. Data represent the means 
±S.E.M. (n=3). *P<0.05 vs PD 98059 or Dex alone treatment; #P<0.05 vs control.
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dexamethasone (100 nM) alone decreased cell viability in 
both ALL cell lines (Figure 5B, 5C). However, association 
of dexamethasone and PD98059 markedly decreased ALL 
cells viability at the same time interval (Figure 5B, 5C). 
The effect of dexamethasone alone on cell death was dose-
dependent and co-treatment with PD98059 potentiated 
this effect (Figure 5D). Concentration of dexamethasone 
as low as 50 nM significantly decreased cell viability in 
association with 5 μM of PD98059 (Figure 5D). The dose-
response graph of PD98059 indicated that concentrations 
as low as 2 μM PD98059 significantly increased the 
lethality of 100 nM dexamethasone in ALL cell lines 
(Figure 5E).
We next examined whether the effects of MEK 
inhibitor on dexamethasone-induced ALL cells death 
were mediated through modulating mitochondrial 
functions. To this end, ALL cells were pretreated with or 
without PD98059 (5 μM) for 30 min and then exposed to 
dexamethasone (100 nM) for 24 h. As shown in Figure 6, 
and in agreement with the MTT results, dexamethasone-
induced Δψm collapse (Figure 6A, 6B) and ROS 
production (Figure 6C, 6D) were significantly increased by 
PD98059 in ALL cells. A consequence of ROS production 
and Δψm collapse is the initiation of mitochondria-
mediated cell apoptosis cascade in which cytochrome c 
release and caspase-3 activity play a critical role [17]. We 
next determined whether the influence of PD98059 on 
dexamethasone-induced ALL cells death is associated with 
the release of cytochrome c and the activity of caspase-3. 
As shown in Figure 6, both cytochrome c release (Figure 
6E, 6F) and caspase-3 activity (Figure 6G, 6H) induced by 
dexamethasone were markedly potentiated by PD98059. 
These data indicate that ERK1/2 signaling pathway 
contributes to attenuate dexamethasone-induced apoptosis 
in ALL cells by limiting Δψm collapse, ROS production, 
and cytochrome c release from mitochondria followed by 
caspase-3 activity.
Bapta-AM potentiates the dexamethasone-
induced inhibition of ERK1/2 signaling and 
apoptosis in primary ALL cells
To confirm the clinical relevance of these results, 
ALL blasts obtained from the peripheral blood of three 
Figure 6: MEK inhibitor, PD98059, enhances dexamethasone-induced apoptosis in ALL cells. ALL cells were treated 
with PD98059 (5 μM) and dexamethasone (Dex, 100 nM) alone or in combination for 24 h. The fluorescence intensity for mitochondrial 
membrane potential changes (A, B), intracellular reactive oxygen species generation (C, D), cytochrome c release (E, F) and caspase 3 
activity (G, H) was measured with SAFAS Xenius XC Spectrofluorometer. Data represent the mean ± S.E.M. (n=3). *P<0.01 vs Dex alone 
treatment; #P<0.05 vs control.
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leukemic patients were isolated and treated ex vivo 
with dexamethasone and/or Bapta-AM and PD98059. 
The results obtained correlate perfectly with those 
obtained in ALL cell lines. We observed that addition 
of dexamethasone (100 nM) induced a rise in [Ca2+]i in 
primary blasts from ALL patients (Figure 7A, 7B, 7C). 
dexamethasone-induced increases in [Ca2+]i were higher 
in Ca2+-containing, as compared with Ca2+-free, buffer 
(Figure 7A, 7B, 7C), suggesting, that dexamethasone 
significantly raised the peak of the Ca2+ elevation 
resulting from extracellular Ca2+ influx. In agreement, 
we observed that dexamethasone significantly boosted 
the subsequently evoked SOCE in primary ALL cells, 
which was blocked in the presence of SOCE inhibitor 
(Figure 7D). We also found that in the presence of Bapta-
AM, dexamethasone failed to trigger cytosolic calcium 
elevation in blasts from ALL patient #1 (Figure 8A) and 
patient #3 (Figure 8B), as well as in patient #2 (data not 
shown). It was also found that dexamethasone slightly 
decreased the phosphorylation of ERK, whereas Bapta-
AM completely suppressed ERK1/2 activation, suggesting 
that Ca2+ is a critical upstream factor that determined 
ERK1/2 phosphorylation (Figure 8C, 8D). Concurrently, 
in comparison to dexamethasone alone treatment, Bapta-
AM greatly enhanced dexamethasone-induced inhibition 
of ERK1/2 phosphorylation, which may be due to the 
inhibitory action of this Ca2+ chelator on dexamethasone-
induced Ca2+ influx (Figure 8C, 8D). Next, we assessed 
whether Bapta-AM or PD98059 would enhance primary 
ALL cells sensitivity to dexamethasone. Using apoptosis 
and MTT assays, we observed that cell viability of ALL 
patients was significantly decreased when cells were co-
Figure 7: Dexamethasone stimulates intracellular Ca2+ release and SOCE in primary blasts from ALL patients. Primary 
blasts were loaded with Fura-2/AM, and the changes in intracellular Ca2+, [Ca2+]i, (F340/F380) were monitored. The colored time-lapse images 
and the graphical representation show the changes in [Ca2+]i evoked by dexamethasone (Dex), respectively, in Ca2+-containing and in Ca2+-
free buffer (A, B, C). (D) Effect of Dex on SOCE activation. SOCE was monitored as Figure 3. (Data are mean ± SEM (n = 5). *p <0.001 
vs. control; #p <0.001 vs. Dex.
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treated with dexamethasone (100 nM) and Bapta-AM 
(1 μM) or PD98059 (5 μM) compared with untreated 
cells or with cells exposed to these agents separately at 
the same doses (Figure 9A, 9B), confirming our above 
results observed in ALL cell lines. We next determined 
whether the influence of Bapta-AM or PD98059 on 
dexamethasone-induced apoptosis is associated with the 
activity of caspase-3. As shown in Figure 9, caspase-3 
activity induced by dexamethasone was markedly 
potentiated by both Bapta-AM (Figure 9C) and PD98059 
(Figure 9D). In addition, we next tested whether 
glucocorticoid-independent increases in [Ca2+]i levels 
could inhibit or protect ALL cells from dexamethasone-
mediated cell death. Thus, the ability of thapsigargin 
(TG) to protect ALL cells from dexamethasone-evoked 
cell apoptosis was evaluated through the regulation of 
caspase-3 activity. TG induces a sustained Ca2+ influx 
in immune cells by depleting intracellular Ca2+ stores 
and stimulated ERK1/2 activation in a Ca2+-dependent 
manner [21]. In this study, we confirmed the effect of TG 
on cytosolic Ca2+ influx and observed that TG stimulated 
ERK1/ERK2 phosphorylation at the same time (Figure 
9E), suggesting the implication of calcium influx in ERK 
activation, as demonstrated elsewhere [21]. Interestingly, 
pre-incubation with TG prevented dexamethasone-
induced ALL cells apoptosis measuring by caspase-3 
activation (Figure 9F). This inhibitory effect of TG on 
dexamethasone-stimulated caspase 3 activation may 
be due to the activation action of TG on ERK signaling 
pathway as prior addition of PD98059 prevented TG effect 
to curtail the dexamethasone-evoked caspase-3 activation 
in these cells (Figure 9F). These data together suggest 
that intracellular Ca2+-related ERK1/2 signaling pathway 
attenuates dexamethasone sensitivity by limiting caspase-
dependent apoptotic pathway.
DISCUSSION
Several studies have reported that disturbances 
in cellular calcium homeostasis are responsible for 
several diseases such as human lymphocytic leukemia 
[22]. Dexamethasone, a synthetic glucocorticoid, has 
been shown to increase or disrupt intracellular calcium 
homeostasis [7–10]. But, in most studies, glucocorticoids 
increased cytosolic calcium concentrations [23], and 
this is consistent with our observations reported here. 
In this study, we showed that dexamethasone induced a 
rapid increase in [Ca2+]i that was significantly reduced 
Figure 8: Bapta-AM potentiates dexamethasone-induced inhibition of ERK1/2 signaling by chelating Ca2+ signaling in 
primary blasts from ALL patients. (A, B) Primary blasts were exposed to 100 nM dexamethasone (Dex) with or without preincubated 
(20 minutes) with Bapta-AM (5 μM) in Ca2+ buffer and the changes in [Ca2+]i were monitored as Figure 5. (C) ALL blasts were preincubated 
(20 min) with Bapta-AM (5 μM) in Ca2+ buffer and then exposed to 100 nM Dex for 5 min. Cell lysates were subjected to western blotting 
analysis with the indicated antibodies, along with quantification (D). Data represent the mean ± SEM (n=3).
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in Ca2+-free buffer in ALL cell lines and primary blast 
from ALL patients, suggesting that dexamethasone 
stimulates Ca2+ from intracellular pool, possibly via 
phospholipase C (PLC). Indeed, a selective inhibitor 
of PLC (U73122), curtailed dexamethasone-evoked 
Ca2+ signaling. As reported in cultured L6 myotubes 
[23], the present study confirms the participation of 
SOC channels in dexamethasone-mediated intracellular 
Ca2+ elevation. However, how this elevated-calcium 
stimulates dexamethasone sensitivity or resistance is 
not clear. Here, we provide evidence that pretreatment 
with intracellular Ca2+chelator (Bapta-AM) significantly 
prevented dexamethasone-induced elevation of [Ca2+]i 
level and potentiated dexamethasone-mediated apoptosis 
in ALL cell lines and primary blasts. ERK1/2 signaling 
pathway is a significant downstream substrate for Ca2+ 
ions, thus, increases in [Ca2+]i phosphorylated ERK1/2 
proteins [13, 14]. Thus, we hypothesized that intracellular 
Ca2+ attenuates dexamethasone sensitivity and apoptosis 
by sustaining Ca2+-dependent ERK1/2 phosphorylation. 
We found that dexamethasone slightly decreased ERK1/2 
phosphorylation in ALL cell lines and primary blasts, 
and depleting intracellular Ca2+ by Bapta-AM markedly 
enhanced inhibition of ERK1/2 pathway, suggesting a 
Ca2+-dependent mechanism. To shed light on the role of 
ERK1/2 activities on dexamethasone sensitivity, PD98059, 
a pharmacological inhibitor of ERK1/2 pathway [1], was 
used. We observed that PD98059 significantly enhanced 
dexamethasone-induced cell death. Our findings strongly 
suggest that Ca2+-related ERK1/2 activation attenuates 
dexamethasone sensitivity. Importantly, genomic data 
with functional screen have demonstrated that down 
regulation of mitogen-activated protein kinases (MAPKs) 
including ERK1/2, by shRNA increased glucocorticoid 
(prednisolone) sensitivity in ALL cells and primary 
blasts [2].
Mitochondria play a crucial role in the induction 
of cell apoptosis. It has been demonstrated that 
dexamethasone induced Δψm collapse and ROS 
production [7, 24]. In the present study, we found that 
intracellular calcium and ERK1/2 signaling pathway 
attenuate dexamethasone-induced Δψm collapse and 
ROS production in ALL cells. This is supported by the 
findings that chelating intracellular calcium with Bapta-
AM or inhibiting ERK1/2 with PD98059 markedly 
enhanced dexamethasone-mediated Δψm collapse and ROS 
Figure 9: Dexamethasone-induced apoptosis is enhanced by chelating Ca2+ signaling and inhibition of ERK1/2 pathway 
in primary blasts from ALL patients. (A) Apoptotic cells were measured by annexin V/FITC-PI staining followed by FACS analysis 
after 48 hours of treatment in ALL blasts. The percentage of cell viability was calculated by annexin V-FITC negative and PI-negative 
population and the values of control cells were considered as 100%. (B) Cell viability was detected by MTT metabolic colorimetric assay. 
The values of control cells were considered as 100%. Data represent the means ±SEM of triplicates. (C, D) Caspase 3 activity was measured 
with SAFAS Xenius XC Spectrofluorometer. *P<0.01 vs Dex alone treatment; #P<0.05 vs control. Data are mean ± SEM (n = 8). (E) Effect 
of thapsigargin (TG, 1 μM) on the changes in intracellular Ca2+ and ERK1/2 phosphorylation. (F) Effect of TG (100 nM) on Dex-induced 
caspase 3 activity. Data are mean ± SEM (n = 3).
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overproduction. These two events lead to mitochondria-
mediated pro-apoptotic factors release such as cytochrome 
c and activity of caspase-3 [25]. In this report, we also 
noticed that by depleting intracellular calcium with Bapta-
AM or inhibiting ERK1/2, the cytochrome c release 
and caspase-3 activation were significantly potentiated 
after dexamethasone exposure. These observations were 
supported in part by Rambal et al. [1], who have shown 
that MEK inhibitors potentiate dexamethasone-evoked 
cytochrome c release in ALL cells.
A pivotal question examined in this study is how 
intracellular calcium elevation by dexamethasone plays a 
central role in mediating dexamethasone sensitivity and 
resistance. It has been proposed previously that cytosolic 
calcium elevation by glucocorticoid is an important step in 
dexamethasone-evoked apoptosis, based on evidence that 
EGTA or Bapta reduced calcium signaling and protected 
CEM-C7 cells from glucocorticoid-induced apoptosis 
[26]. This is not supported by the findings reported in the 
current study. This difference might be due to the different 
cell types used in our current report and this earlier study, 
another possibility is due to the difference in calcium 
chelator concentrations used. Our finding is consistent 
with studies conducted using the same cells (i.e. CEM-C7) 
that shown that calcium chelator EGTA increased DNA 
fragmentation and enhanced dexamethasone effect, and 
concluded that massive calcium influx is not responsible 
for the initiation of glucocorticoid-mediated cell apoptosis 
[27]. In addition, studies conducted using mouse T-cells 
and DT40 cells that found that inhibiting IP3-gated 
calcium channels did not inhibit dexamethasone-induced 
apoptosis [28, 9]. Furthermore, previous findings 
demonstrated that glucocorticoid-induced bone cell death 
was prevented by the calcium-binding protein calbindin-
D28k through ERK1/2 signaling pathway activation 
associated with caspase-3 inhibition [29].
Overall, our results suggest that intracellular 
Ca2+-related ERK1/2 signaling pathway attenuates 
dexamethasone sensitivity and apoptosis in ALL cells by 
decreasing Δψm collapse, ROS production, cytochrome c 
release from mitochondria, and caspase-3 activation. This 
report provides a novel resistance pathway underlying the 
regulatory effect of dexamethasone on ALL cells.
MATERIALS AND METHODS
Cell lines and reagents
The human leukemia cell lines Nalm-6 and Reh 
(DSMZ®, Deutschland) were cultured in RPMI 1640 
medium containing 10% fetal bovine serum, 2 mM of 
L-glutamine with 5000 UI/L penicillin and 50 mg/L 
streptomycin (Eurobio®, France), and maintained at 37°C 
in a 5% CO2 humidified atmosphere. Fura-2/AM, Rhod-
2/AM, Bapta-AM, U73122, SKF96365 and thapsigargin 
were purchased from Abcam Biochemicals, France. 
Poly-D-lysine, dimethylsulfoxide (DMSO), 2APB and 
dexamethasone were purchased from Sigma Aldrich, 
France. PD98059 was purchased from Euromedex, 
France. Antibodies to total (Erk1/2) and phosphorylated-
Erk1/2 (pErk1/2) were obtained from Cell signaling Inc, 
France.
Human tumor samples
Primary blasts from 3 patients diagnosed 
with ALL samples (peripheral blood) were used 
(Table 1). Informed consent was obtained following 
Table 1: Clinical and immunological characteristics on patients with ALL included in the study
Characteristics Patient #1 Patient #2 Patient #3
Sex F F F
Age at diagnosis (months) 20 104 1.5
Le (x 109/L) 72 315 430
% of leukemic blasts >80 > 85 > 90
Immunological phenotype B T B
Cell surface molecules
CD10+
CD19+
CD22+
CD24+
CD38+
CD79a+
CD3+
CD5+
CD7+
CD10+
CD34+
CD38+
CD10-
CD19+
CD22+
CD34+
CD36+
CD79a+
Cytogenetic normal normal MLL/AF4+; t (4;11)+
MRD at day 35 - < 0.5% -
Chemotherapy(sensitivity) + + -
Le: leukocytes numbers; ALL: acute lymphoblastic leukemia; MRD: minimal residual disease.
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institutional guidelines and protocols were approved 
by the institutional review board of Rouen University 
and Hospital Center according to the Declaration of 
Helsinki. Mononuclear cells were isolated by Ficoll-
hypaque centrifugation. Cells (> 80% blasts) were 
cryopreserved and stored in liquid nitrogen until use. 
After thawing, cells were maintained in RPMI 1640 
medium supplemented as described above.
Cell viability assay
Cultured cells (5 x 104 cells/well) were seeded in 
96-well culture plates with or without test compounds. 
After 48 hours, MTT assay was used to assess cell 
viability. Culture medium was aspirated, 100 μl serum 
free medium and 10 μl MTT solution (5 mg/ml) were 
added to each well, and the plates were incubated at 
37°C for 3 hours. The medium was aspirated and 50 μl 
DMSO was added to each well to dissolve the formazan 
crystals. After 15 min at 37°C, the absorbance was read 
at 540 nm.
Imaging and measurement of intracellular 
calcium [Ca2+]i levels
The cells were cultured on krystal 24-well glass 
bottom (Proteigene, France) coated with poly-D-lysine 
and then incubated with Fura-2/AM (5 μM) diluted in 
culture medium for 60 min at 37°C. After loading, cells 
were washed three times (600g x 10 min) and remained 
suspended in a buffer solution containing: 110 mM, NaCl; 
5.4 mM, KCl; 25 mM, NaHCO3; 0.8 mM, MgCl2; 0.4 mM, 
KH2PO4; 20 mM, Hepes; 0.33 mM, Na2HPO4; 1.2 mM, 
CaCl2, pH adjusted to 7.4. For experiments in Ca
2+-free 
medium, CaCl2 was replaced by EGTA (2 mM). SOCE 
was determined in Ca2+-free medium and subsequent Ca2+ 
re-addition in the presence of thapsigargin (1 μM) [20]. 
The fluorescence intensity of Fura-2/AM was measured 
at Ex 340 and 380 nm and Em 510 nm under the Leica 
DMI6000 B inverted microscope (Leica, France). The 
changes in intracellular Ca2+ were calculated as ΔRatio 
(F340/F380). Results were averaged from the individual 
cells (20-30 cells in a single run) with at least three 
independent experiments.
Measurement of mitochondrial Ca2+ response, 
[Ca2+]m
Mitochondrial calcium ([Ca2+]m) was measured by 
loading ALL cells with the cell permeable Ca2+-indicator 
rhod-2/AM (2 μM; dissolved in DMSO) in RPMI for 1 
h at 37 °C, and then washed three times in rhod-2-free 
medium. To determine [Ca2+]m, rhod-2 was excited at 
λex (552 nm), and fluorescence was recorded at λem 
(581 nm).
Mitochondrial membrane potential (ΔΨm) 
measurement
Mitochondrial membrane potential was measured 
using the cationic dye JC-10 (a fluorescent ΔΨm dye, 
Santa Cruz Inc., Germany). This dye is red in polarized 
mitochondria and green in depolarized mitochondria. 
ALL cell lines were incubated with Bapta-AM (5 μM) 
or PD98059 (5 μM) for 30 min then stimulated with 
dexamethasone (100 nM) for 24 hours before loaded 
with 20 μM of JC-10 for 30 min at 37°C. After washing, 
the fluorescence intensity for both J-aggregates and 
monomeric forms of JC-10 was measured using SAFAS 
Xenius XC Spectrofluorometer (MC 98000 Monaco) at Ex 
485 nm/Em520 and 595 nm.
Intracellular reactive oxygen species (ROS) 
measurement
ALL cell lines were treated with Bapta-AM (5 
μM) or PD98059 (5 μM) for 30 min then stimulated with 
dexamethasone (100 nM) for 24 hours. Cells were then 
loaded with 20 μM of Dihydrorhodamine 123 (DHR 123, 
a fluorescent probe for the detection of reactive oxygen 
species, Santa Cruz Biotechnology Inc., Heidelberg, 
Germany) for 30 min at 37°C. Cells were washed twice 
with PBS buffer after dye loading and the fluorescence 
intensity of Rhodamine 123 was measured with 
Spectrofluorometer SAFAS Xenius XC at Ex 500 nm/
Em536 and by absorbance spectroscopy at 500 nm.
ELISA cytochrome c measurement
ALL cell lines were treated with Bapta-AM (5 
μM) or PD98059 (5 μM) for 30 min then stimulated with 
dexamethasone (100 nM) for 24 hours. The measurement 
of cytochrome c release was evaluated using the enzyme 
linked immunosorbent assay (ELISA) kits (Abcam 
Biochemicals, France) according to manufacturer’s 
instructions.
Measurement of caspase 3 activity
Activity of caspase-3 was measured using Ac-
DEVD-AFC substrate (Enzo Life Sciences (ELS) AG, 
Villeurbanne, France), according to the manufacturer’s 
instructions. Briefly, ALL cell lines were treated with 
Bapta-AM (5 μM) or PD98059 (5 μM) for 30 min then 
stimulated with dexamethasone (100 nM) for 24 hours, 
and then collected and lysed in cell lysis buffer (HEPES 
50 mM, NaCl 100 mM, DTT 10 mM, CHAPS 0.1%, 
EDTA 1 mM, pH 7.4). 20 μg of cell lysate was added 
to 100 μL of caspase-3 buffer containing 40 μM of the 
caspase-3 substrate Ac-DEVD-AFC (fluorogenic) as 
final concentration and incubated at 37°C for 1 h in the 
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dark. Caspase-3 activity was assessed by measuring 
fluorescence at excitation wavelength of 400 nm and 
emission wavelength of 505 nm using SAFAS Xenius XC 
Spectrofluorometer (MC 98000 Monaco).
Apoptosis assay
Apoptotic cells were determined by Annexin 
V-FITC/PI staining (Abcam Biochemicals, France) 
according to the instruction. The percentage of annexin 
V-FITC and propidium iodide-positive cells were assessed 
by flow cytometry using BD FACSCanto II flow cytometer 
(BD Biosciences, USA). All flow cytometry data were 
analyzed using FlowJo 10.1 for Macintosh (Ashland, OR, 
USA).
Cell cycle analysis
ALL cells were treated with or without test 
compounds for 48 hours and then washed with cold 
PBS and fixed with cold 70% ethanol for 30 mn at room 
temperature. After washing with PBS, cells were incubated 
in the dark for 15 mn with 1 mg/ml RNase A, 1 mg/ml 
propidium iodide. Cell-cycle distribution was determined 
by PI staining using flow cytometry and analyzed by 
FlowJo 10.1.
Western blotting
ALL cell lines and primary blasts from ALL patients 
were incubated with Bapta-AM (5 μM) and PD98059 (5 
μM) for 20 min and then stimulated with dexamethasone 
(100 nM) for 5 min, and lysed in 50 μl of RIPA buffer 
(Sigma-Aldrich, St-Quentin Fallavier, France) containing 
freshly added protease and phosphatase inhibitors 
(Pierce Biotechnology, Perbio Science, Rockford, USA). 
Proteins (40 μg) were loaded on 10 % SDS-PAGE gels 
and transferred to a nitrocellulose membrane. 5 % fat free 
milk in TBS with 0.1 % tween-20 (TBST) was used for 
blocking at room temperature for 1 h, then, membranes 
were incubated with anti-pErk1/2 and anti-Erk1/2 (Cell 
signaling, Ozyme, Yvelines, France) overnight at 4°C. 
After three times washing with TBST, blots were incubated 
with secondary antibodies-linked horseradish peroxidase 
(anti-mouse and anti-rabbit, Cell signaling, Ozyme, 
Yvelines, France) for 1 h at room temperature. Proteins 
were visualized with enhanced chemiluminescence 
reagents (GE Healthcare, Amersham, UK).
Statistical analysis
Data are expressed as mean ± SEM values from at 
least three independent experiments. Statistical analyses 
were conducted with the PRISM Software (GraphPad 
Software, USA) using t test. Differences were considered 
statistically significant at p<0.05.
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